[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344969-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-344969-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","isgylation-prevents-autophagic-degradation-of-sting-and-promotes-antitumor-immunity-in-lung-cancer","ISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer","","The study examines why STING protein levels decline during lung cancer progression and how this limits the efficacy of STING-based immunotherapies. It identifies ISGylation as a stabilizing mechanism that blocks autophagic degradation of STING and enhances its immunostimulatory function. USP18 is defined as a negative regulator removing ISGylation from STING, while Tanshinone IIA sulfonate (TST) inhibits USP18, increasing STING ISGylation. Combined with the STING agonist diABZi, TST synergizes to increase NK1.1+ cell infiltration and suppress tumor growth in lung cancer models, supporting STING ISGylation as a therapeutic target.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/isgylation-prevents-autophagic-degradation-of-sting-and-promotes-antitumor-immunity-in-lung-cancer/344969/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/isgylation-prevents-autophagic-degradation-of-sting-and-promotes-antitumor-immunity-in-lung-cancer/344969.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"How does ISGylation affect STING in lung cancer?","Question",{"text":62,"@type":63},"ISGylation stabilizes STING by preventing its autophagic degradation, thereby enhancing STING’s immunostimulatory function.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What role does USP18 play in STING regulation?",{"text":67,"@type":63},"USP18 acts as a negative regulator by removing ISGylation from STING through deconjugation.",{"name":69,"@type":60,"acceptedAnswer":70},"How do TST and diABZi work together to suppress tumors?",{"text":71,"@type":63},"TST inhibits USP18 to enhance STING ISGylation and stabilize STING, and when combined with the STING agonist diABZi it produces a synergistic antitumor immune response, including increased NK1.1+ infiltration and stronger tumor growth suppression in lung cancer models.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},344969,1790177751,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer  \nDan Cao1,5, Bin Huang 1,2,5, Xinming Fu1, Ming Liu1, Xiaogang Niu3, Hongbin Zhai 1 and Hao Huang 1,4 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | The STING pathway plays a central role in immune activation; however, STING protein levels decline during the progression of various cancers, including lung cancer, thereby limiting the efﬁcacy of immunotherapies. Our study uncovers a previously unrecognized mechanism whereby ISGylation stabilizes STING by preventing its autophagic degradation, thereby enhancing its immunostimulatory function. Moreover, we demonstrate USP18 as a negative regulator that removes ISGylation from STING, and identify Tanshinone IIA sulfonate (TST) as a potent USP18 inhibitor that enhances STING ISGylation and stabilizes STING protein levels. When combined with the STING agonist diABZi, TST exhibits a synergistic effect, eliciting a potent antitumor immune response by increased inﬁltration of NK1.1⁺ cells and pronounced suppression of tumor growth in lung cancer models. These ﬁndings underscore the therapeutic potential of targeting STING ISGylation, particularly in patients with low STING expression who |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| often respond poorly to current STING-targeted therapies. |  |  |\n|  | Cell Death and Disease (2026)17:271; [https://doi.org/10.1038/s41419-026-08527-1](https://doi.org/10.1038/s41419-026-08527-1) |  |\n|  |  |  |\n\nINTRODUCTION  \nThe cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is a key sensor of aberrant cytoplasmic DNA, driving both innate and adaptive immune responses [1] . Upon DNA binding, cGAS catalyzes the production of the second messenger cGAMP, which subsequently activates STING [2–4] . This activation recruits TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3), promoting type I interferon (IFN-I) production [5] . The resulting immune response includes dendritic cell maturation, antitumor macrophage polarization, T cell activation, and natural killer (NK) cell activation [6–8] .  \nThe cGAS-STING signaling pathway is often suppressed in various cancers, with reduced expression of cGAS or STING in tumor cells linked to poorer clinical outcomes [9–12] . The downregulation is associated with tumor immune evasion, hindering effective immune surveillance [13] . Therefore, enhancing STING stability is pivotal for optimizing STING mediated anticancer immunotherapy and presents a promising target for chemical intervention. Despite the therapeutic promise of targeting this pathway, the clinical translation of STING agonistshave faced signiﬁcant hurdles. Various STING agonists, includingthe non-cyclic dinucleotide (CDN) agonist DMXAA [14], the synthetic CDN agonist MK-1454 [15], the small molecule diABZi [16], and MSA-2 [17], have been discovered to activate the STING pathway for cancer therapy, showing promising results in preclinical mouse models. However, current clinical trials of STING agonists, either as monotherapy or in combination with immune  \ncheckpoint PD-1/PD-L1 inhibitors, have shown less than optimal antitumor effects [18–20] . These ﬁndings suggest unknown mechanisms may be limiting their therapeutic efﬁcacy.  \nRestoring effective immunosurveillance in STING-deﬁcient tumors requires a clear understanding of the mechanisms regulating STING protein stability. STING homeostasis is governed by a multilayered network of post-translational modiﬁcations (PTMs) that determine its activation, trafﬁcking, and degradation [21–23] . For example, palmitoylation of STING at Cys88/91 is indispensable for signal initiation [23], whereas phosphorylation of STING by TBK1 [5] or ULK1 [24] modulates downstream its activity and turnover. Multiple E3 ligases, including RNF5 [25] and TRIM29 [2","cbCainvQvnhNzB4D","https://ap.wps.com/l/cbCainvQvnhNzB4D","pdf",4021026,14,"English","# Introduction\n## cGAS-STING pathway and immunotherapy limitations\n## STING stability and post-translational modifications\n## Autophagy-lysosome–mediated STING clearance\n## Role of ISGylation and USP18","[{\"question\":\"How does ISGylation affect STING in lung cancer?\",\"answer\":\"ISGylation stabilizes STING by preventing its autophagic degradation, thereby enhancing STING’s immunostimulatory function.\"},{\"question\":\"What role does USP18 play in STING regulation?\",\"answer\":\"USP18 acts as a negative regulator by removing ISGylation from STING through deconjugation.\"},{\"question\":\"How do TST and diABZi work together to suppress tumors?\",\"answer\":\"TST inhibits USP18 to enhance STING ISGylation and stabilize STING, and when combined with the STING agonist diABZi it produces a synergistic antitumor immune response, including increased NK1.1+ infiltration and stronger tumor growth suppression in lung cancer models.\"}]","ISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer | PDF",1790056010,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e1b30d6b82a4cbd595590b2b01b69ed.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63069cf079dcf901b8b32881af100fcc.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8d66ac1f68e6f5c28b9a403dd1cbf8d.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4f4128495b81f444ee7dda368ff63e3.webp",980,1301]